A blood test to determine the risks of preeclampsia and severe preeclampsia in pregnant patients has been given approval by the FDA.
The FDA has approved a test for screening preeclampsia in pregnant women.
Preeclampsia is a complication present in 1 in 25 pregnancies and is more often seen in Black women than White women.1 The condition causes high blood pressure and protein in the urine which can cause kidney and liver damage. Severe preeclampsia may be fatal in some patients.
Over the past 25 years, the prevalence of preeclampsia has risen by 25%, and it is currently the leading cause of maternal mortality and disability worldwide.2 It also increases the risks of preterm birth and pregnancy loss.
Diagnosing preeclampsia has been historically difficult, as there have been no certain methods developed for determining preeclampsia risk, presence, or severity.1 Risk factors of preeclampsia include high blood pressure, diabetes, or obesity before pregnancy, prior preeclampsia, and multiple gestation.
Symptoms include swollen hands, swollen feet, headache, nausea, fatigue, blurry vision, and rapid weight gain. Many patients associate these symptoms with pregnancy and are unaware they are caused by preeclampsia.
The risk of preeclampsia is 60% higher in Black women, kidney problems are 3 times more likely, and the risk of failed pregnancy is increased. Investigators have predicted these disparities may be caused by social, cultural, and biological issues, but are uncertain.
The new blood test measures the 2 proteins put out by the placenta to determine preeclampsia presence. A normal ratio between the 2 proteins indicates a patient does not have preeclampsia, while a disproportionate ratio indicates increased preeclampsia risk, with a direct correlation between the disproportion and risk.
This blood test was developed by Thermo Fisher Scientific and granted approval by the FDA in May 2023.2 It was designed for use in pregnant patients in the hospital with blood pressure disorders.
Delivery is the primary cure for preeclampsia, leading doctors to keep patients at risk of severe preeclampsia in the hospital. As an estimated 6 in 10 deaths from preeclampsia are preventable, the ability to measure severe preeclampsia risk could be lifesaving in many patients.
Reference
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
Tailored hormone therapy improves postoperative endometriosis outcomes
October 3rd 2024A recent study suggests that postoperative endometriosis patients experience improved quality of life through hormone therapies guided by optimizing treatment based on individual hormonal receptor profiles.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Study reports reduced SSI odds after gynecologic surgery from metronidazole and cefazolin
September 19th 2024A recent study shows that adding metronidazole to cefazolin significantly lowers the risk of surgical site infections in gynecologic cancer surgeries, enhancing patient outcomes.
Read More